246 related articles for article (PubMed ID: 30042185)
1. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
McCuaig JM; Stockley TL; Shaw P; Fung-Kee-Fung M; Altman AD; Bentley J; Bernardini MQ; Cormier B; Hirte H; Kieser K; MacMillan A; Meschino WS; Panabaker K; Perrier R; Provencher D; Schrader KA; Serfas K; Tomiak E; Wong N; Young SS; Gotlieb WH; Hoskins P; Kim RH;
J Med Genet; 2018 Sep; 55(9):571-577. PubMed ID: 30042185
[TBL] [Abstract][Full Text] [Related]
2. Genetic testing in ovarian cancer - clinical impact and current practices.
Knabben L; Imboden S; Mueller MD
Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
[TBL] [Abstract][Full Text] [Related]
3. Finding all BRCA pathogenic mutation carriers: best practice models.
Hoogerbrugge N; Jongmans MC
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
[TBL] [Abstract][Full Text] [Related]
4. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
Flaum N; Morgan RD; Burghel GJ; Bulman M; Clamp AR; Hasan J; Mitchell CL; Badea D; Moon S; Hogg M; Hadjiyiannakis D; Clancy T; Schlecht H; Woodward ER; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Lalloo FI; Harkness EF; Evans DGR
Eur J Hum Genet; 2020 Nov; 28(11):1541-1547. PubMed ID: 32651552
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
[TBL] [Abstract][Full Text] [Related]
6. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Pujol P; Barberis M; Beer P; Friedman E; Piulats JM; Capoluongo ED; Garcia Foncillas J; Ray-Coquard I; Penault-Llorca F; Foulkes WD; Turnbull C; Hanson H; Narod S; Arun BK; Aapro MS; Mandel JL; Normanno N; Lambrechts D; Vergote I; Anahory M; Baertschi B; Baudry K; Bignon YJ; Bollet M; Corsini C; Cussenot O; De la Motte Rouge T; Duboys de Labarre M; Duchamp F; Duriez C; Fizazi K; Galibert V; Gladieff L; Gligorov J; Hammel P; Imbert-Bouteille M; Jacot W; Kogut-Kubiak T; Lamy PJ; Nambot S; Neuzillet Y; Olschwang S; Rebillard X; Rey JM; Rideau C; Spano JP; Thomas F; Treilleux I; Vandromme M; Vendrell J; Vintraud M; Zarca D; Hughes KS; Alés Martínez JE
Eur J Cancer; 2021 Mar; 146():30-47. PubMed ID: 33578357
[TBL] [Abstract][Full Text] [Related]
8. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
Burling MJ; Gamet K; Eva L; Tan AL
Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
[TBL] [Abstract][Full Text] [Related]
9. BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
Kwong A; Cheng KD; Hsue CV; Hui SK; Leung CR; Leung KA; Ngan KR; Soong SI
Asia Pac J Clin Oncol; 2019 Mar; 15 Suppl 2():20-31. PubMed ID: 30838787
[TBL] [Abstract][Full Text] [Related]
10. The integration of BRCA testing into oncology clinics.
Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S
Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
12. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
13. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Walsh CS
Gynecol Oncol; 2015 May; 137(2):343-50. PubMed ID: 25725131
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
[TBL] [Abstract][Full Text] [Related]
15. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
[TBL] [Abstract][Full Text] [Related]
17. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
18. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
19. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
Hoskins PJ; Gotlieb WH
CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380
[TBL] [Abstract][Full Text] [Related]
20. Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
Hoskins PJ
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):472-483. PubMed ID: 29735311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
